Wednesday, November 25, 2009, 7:25am EST - Canadian Markets open in 2 hours and 5 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

CombinatoRx Inc. (CRXX)

 On Nov 24: 1.18 USD   0.00 (0.00%)  
MORE ON CRXX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
CombinatoRx, Incorporated (NGM:CRXX) Delayed quote dataEdit
Last Trade: 1.18 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 1.18
Open: N/A
Bid: N/A
Ask: 1.30 x 100
1y Target Est: 12.50
Day's Range: N/A - N/A
52wk Range: 0.25 - 2.60
Volume: 0
Avg Vol (3m): 900,845
Market Cap: 41.35M
P/E (ttm): N/A
EPS (ttm): -1.71
Div & Yield: N/A (N/A%)
CombinatoRx Inc. (CRXX)
1d  5d  3m  6m  1y  2y  5y 
 Add CRXX to Portfolio   Download Data

HEADLINES
• FDA delays Combinatorx drug decision
at bizjournals.com (Tue 2:05pm)
• CombinatoRx Oncology Programs to Be Highlighted at ASH 2009
Business Wire (Tue 7:32am)
• COMBINATORX, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 20)
• FDA Extends NDA Review for Exalgo Extended-Release Tablets
Business Wire (Fri, Nov 20)
• BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
at Seeking Alpha (Tue, Nov 17)
• CombinatoRx Shares Fall as Neuromed Drug Not Approved by FDA
at Fox Business (Mon, Nov 16)
• Sprint, CombinatoRx: Early Volume Plays
at TheStreet.com (Mon, Nov 16)
• UPDATE - CombinatoRx: Neuromed pain drug may not get approval
at Reuters (Mon, Nov 16)
• COMBINATORX, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Mon, Nov 16)
• Neuromed Receives FDA Feedback on New Drug Application for Exalgo Extended-Release Tablets
Business Wire (Mon, Nov 16)
• COMBINATORX, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibit
EDGAR Online (Tue, Nov 10)
More Headlines for CRXX...
ANALYST
EPS Est (next year) (Dec-07) : -1.85
EPS Est (in 2 years) (Dec-08) : -1.81
Avg Rec (current)*: 1.3
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
CombinatoRx, Incorporated, a biopharmaceutical company, focused on developing synergistic combinations of approved drugs, with a portfolio of product candidates in clinical development.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices